News
ANAB
54.92
-0.51%
-0.28
Closing Bell Movers: Vicor jumps 13% on Q3 pre-announcement
TipRanks · 14h ago
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 16h ago
AnaptysBio Q2 Adj. EPS $(0.11) Beats $(0.46) Estimate, Sales $27.488M Beat $21.675M Estimate
Benzinga · 17h ago
AnaptysBio GAAP EPS of $5.11 beats by $5.02, revenue of $27.5M beats by $7.38M
Seeking Alpha · 17h ago
AnaptysBio reports Q2 diluted EPS $5.11 vs. ($1.30) last year
TipRanks · 17h ago
*AnaptysBio 2Q Cont Ops EPS $4.93 >ANAB
Dow Jones · 17h ago
*AnaptysBio 2Q EPS $5.11 >ANAB
Dow Jones · 17h ago
*AnaptysBio 2Q Rev $27.5M >ANAB
Dow Jones · 17h ago
Press Release: Anaptys Announces Second Quarter -2-
Dow Jones · 17h ago
Weekly Report: what happened at ANAB last week (0914-0918)?
Weekly Report · 1d ago
AnaptysBio (ANAB) Gets a Buy from Leerink Partners
TipRanks · 1d ago
Barclays Remains a Buy on AnaptysBio (ANAB)
TipRanks · 4d ago
AnaptysBio's Transformation Into a Royalty Company Meets Its First Real Scorecard—Or Does It
Barchart · 6d ago
AnaptysBio (ANAB) Tests The Royalty Story On Questions Over Whether Shares Are Fully Valued
Simply Wall St · 09/14 10:16
Weekly Report: what happened at ANAB last week (0907-0911)?
Weekly Report · 09/14 10:00
U.S. Earnings Preview: After Market Close Sept. 8
Dow Jones · 09/08 19:30
AnaptysBio's Second Chance to Explain What Happened Last Quarter
Barchart · 09/08 16:01
Weekly Report: what happened at ANAB last week (0831-0904)?
Weekly Report · 09/07 09:55
AnaptysBio (ANAB) Rides A Royalty Driven Narrative, Is The Stock Still A Bargain?
Simply Wall St · 09/06 03:22
U.S. Earnings Preview: After Market Close Sept. 1
Dow Jones · 09/01 19:30
More
Webull provides a variety of real-time ANAB stock news. You can receive the latest news about Anaptysbio Inc through multiple platforms. This information may help you make smarter investment decisions.
About ANAB
AnaptysBio, Inc. is a royalty management company. The Company manages the financial collaborations for Jemperli with GlaxoSmithKline (GSK) and imsidolimab with Vanda Pharmaceuticals Inc. (Vanda). The Company's financial collaboration with GSK is focused upon the development and commercialization of Anaptys-discovered Jemperli (dostarlimab), a PD-1 antagonist, approved for endometrial cancer and dMMR pan tumors, and is being studied in rectal cancer, colon cancer and head and neck squamous cell carcinoma. The Company's financial collaboration with Vanda is focused upon the development and commercialization of Anaptys-discovered imsidolimab, an IL-36R antagonist, which is being developed for generalized pustular psoriasis (GPP).